Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingAug 20, 2025Amlodipine and Olmesartan Medoxomil TabletsFailed Dissolution Specifications: low dissolution resultsAscend Laboratories, LLC · D-0576-2025Class IIOngoingAug 20, 2025LevoxylSubpotent drugPfizer · D-0575-2025Class IIOngoingAug 13, 2025Spironolactone TabletsPresence of foreign substance: identified as aluminum.Sun Pharmaceutical Industries Inc · D-0574-2025Class IIOngoingAug 13, 2025RECOMBINATECGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.Cardinal Health Inc. · D-0573-2025Class IIOngoingAug 13, 2025Xolair (omalizumab injection)CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.Cardinal Health Inc. · D-0572-2025Class IIOngoingAug 13, 2025Xolair (omalizumab injection)CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.Cardinal Health Inc. · D-0571-2025Class IIOngoingAug 13, 2025Duloxetine D/RCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.Direct Rx · D-0568-2025Class IIOngoingAug 13, 2025Duloxetine D/RCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.Direct Rx · D-0567-2025Class IIOngoingAug 13, 2025Doxepin Hydrochloride CapsulesCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.Alembic Pharmaceuticals Limited · D-0566-2025Class IIOngoingAug 13, 2025Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0565-2025Class IIOngoingAug 13, 2025Semaglutide + Cyanocobalamin injection solutionLack of Processing Controls.Aequita Pharmacy · D-0564-2025Class IIOngoingAug 13, 2025Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0563-2025Class IIOngoingAug 13, 2025Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0562-2025Class IIOngoingAug 13, 2025Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0561-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0560-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 13.2 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0559-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 11.24 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0558-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 8.8 mg + 1.0mg/0.5 ml Inj SolLack of Processing Controls.Aequita Pharmacy · D-0557-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 6.6 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0556-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 4.4 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0555-2025Class IIOngoingAug 13, 2025Tirzepatide + Niacinamide 2.2 mg + 1.0mg/0.5 mL Inj SolLack of Processing Controls.Aequita Pharmacy · D-0554-2025Class IIOngoingAug 13, 2025Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj SolLack of Processing Controls.Aequita Pharmacy · D-0553-2025Class IIOngoingAug 13, 2025Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limitBreckenridge Pharmaceutical, Inc. · D-0552-2025Class IIOngoingAug 6, 2025Lorazepam InjectionFailed Impurities/Degradation Specifications: An out-of-Specification for total related compoundsHikma Pharmaceuticals USA Inc. · D-0551-2025Class IIOngoingAug 6, 2025Sucralfate TabletsCGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet...Nostrum Laboratories, Inc. · D-0547-2025Class IIOngoingAug 6, 2025Cinacalcet Tablets 90 mgFailed Dissolution Specifications.Strides Pharma, Inc. · D-0546-2025Class IIOngoingAug 6, 2025Bicillin L-ACGMP Deviations; particulates identified during visual inspectionPfizer Inc. · D-0545-2025Class IIOngoingAug 6, 2025Bicillin L-ACGMP Deviations; particulates identified during visual inspectionPfizer Inc. · D-0544-2025Class IIOngoingAug 6, 2025Timolol Maleate Ophthalmic Solution USPDefective Container: spike of the cap becomes lodged in the nozzle of the product bottle.FDC Limited · D-0543-2025Class IITerminatedAug 6, 2025Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mgLabeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027Lupin Pharmaceuticals Inc. · D-0542-2025Class IIOngoingJul 30, 2025Budesonide Inhalation SuspensionLack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.Cipla USA, Inc. · D-0541-2025Class IIOngoingJul 30, 2025BENLYSTACGMP Deviations; potential temperature excursions due to transit delaysMckesson Medical-Surgical Inc. Corporate Office · D-0540-2025Class IIOngoingJul 30, 2025EVENITYCGMP Deviations; potential temperature excursions due to transit delaysMckesson Medical-Surgical Inc. Corporate Office · D-0539-2025Class IIOngoingJul 30, 2025PROLIA (denosumab)CGMP Deviations; potential temperature excursions due to transit delaysMckesson Medical-Surgical Inc. Corporate Office · D-0538-2025Class IITerminatedJul 30, 2025clomiPRAMINE Hydrochloride Capsules USP 25 mgFailed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during retention...Lupin Pharmaceuticals Inc. · D-0537-2025Class IIICompletedJul 30, 2025Tropicamide-Proparacaine-Phenylephrine-KetorolacSub-Potent Drug: Subpotent assay results during stability testing.Imprimis NJOF, LLC · D-0536-2025Class IICompletedJul 30, 2025Epinephrine Lidocaine HCLSub-Potent Drug: Subpotent assay results during stability testing.Imprimis NJOF, LLC · D-0535-2025Class IIOngoingJul 23, 2025Shave and Skincare Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant/DeodorantCGMP DeviationsA.P. Deauville, LLC · D-0550-2025Class IIOngoingJul 23, 2025Beauty & Skincare Power Stick original nourishing invisible protection roll-on Antiperspirant/Deodorant...CGMP DeviationsA.P. Deauville, LLC · D-0549-2025Class IIOngoingJul 23, 2025Power Stick for her PH Balanced Roll-On Antiperspirant Deodorant with Powder Fresh ScentCGMP DeviationsA.P. Deauville, LLC · D-0548-2025

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.